Mottet J J, Horber F F, Casez J P, Descoeudres C, Jaeger P
Medizinische Universitätspoliklinik, Inselspital, Berne, Switzerland.
J Bone Miner Res. 1996 Jan;11(1):96-104. doi: 10.1002/jbmr.5650110114.
It is still unclear whether dialysis modality, i.e., continuous ambulatory peritoneal dialysis (CAPD) versus hemodialysis (HD) specifically affects bone mineral density (BMD). To answer this question, 34 patients on HD and 25 on CAPD were matched for age, sex, height, and body weight with 125 normal subjects. BMD was measured using dual-energy X-ray absorptiometry (DXA; Hologic QDR 1000/W) at the lumbar spine (trabecular bone), the femoral neck (mixed cortical and trabecular bone), the distal tibial diaphysis (cortical bone), and the epiphysis (trabecular bone) in all subjects. No significant difference for blood hemoglobin, albumin, total and ionized calcium, intact parathyroid hormone (PTH) or phosphorus concentrations, as well as for alkaline phosphatase activity, failed renal allograft, prior steroid therapy, prior parathyroidectomy, duration of uremia, or of dialysis was found between patients on HD and those on CAPD. However, the residual daily urine volume and renal function at the time of the absorptiometry were higher in CAPD than in HD patients (p < 0.05) as well as the mean dialysate calcium concentration during dialysis, the blood bicarbonate concentration, and the residual renal function at the initiation of dialysis (p < 0.01, p < 0.05, and p < 0.005, respectively). In contrast, the total dose of calcium carbonate was lower in CAPD than in HD patients (p < 0.01). Results of BMD were expressed as Z scores (the number of standard deviations from the appropriate mean of BMD of 623 healthy subjects adjusted for age and sex). At the lumbar spine, no significant difference with respect to BMD was observed between the three groups. At the femoral neck and tibial epiphysis, HD patients had lower BMD (p < 0.001) than normal controls, whereas no difference was observed between HD and CAPD patients. At tibial diaphysis, patients on HD had lower BMD (p < 0.001) than patients on CAPD and than normal controls, with the values being similar in patients on CAPD and in normal controls. The results remained identical after exact matching of HD (n = 25) and CAPD (n = 25) patients for dialysis duration (1.9 +/- 0.3 and 1.7 +/- 0.3 years, respectively). Multiple regression analysis revealed significant negative correlations between Z scores at the lumbar spine (p < 0.05), femoral neck (p < 0.02), tibial diaphysis (p < 0.005), and tibial epiphysis (p < 0.05) on the one hand and plasma alkaline phosphatase activity on the other. The Z score at tibial diaphysis was also correlated with residual renal function at the initiation of dialysis (p < 0.05). In conclusion, this study provides evidence for the preservation of cortical bone with CAPD as opposed to HD. The higher residual renal function observed in the former treatment modality might account, at least in part, for this finding.
目前仍不清楚透析方式,即持续性非卧床腹膜透析(CAPD)与血液透析(HD)是否会对骨矿物质密度(BMD)产生特异性影响。为回答这个问题,将34例接受血液透析的患者和25例接受持续性非卧床腹膜透析的患者,在年龄、性别、身高和体重方面与125名正常受试者进行匹配。所有受试者均使用双能X线吸收法(DXA;Hologic QDR 1000/W)测量腰椎(松质骨)、股骨颈(皮质骨和松质骨混合)、胫骨干骺端(皮质骨)和骨骺(松质骨)的骨矿物质密度。在接受血液透析的患者和接受持续性非卧床腹膜透析的患者之间,未发现血红蛋白、白蛋白、总钙和离子钙、完整甲状旁腺激素(PTH)或磷浓度以及碱性磷酸酶活性、肾移植失败、既往类固醇治疗、既往甲状旁腺切除术、尿毒症持续时间或透析持续时间有显著差异。然而,持续性非卧床腹膜透析患者的残余每日尿量和骨密度测量时的肾功能高于血液透析患者(p<0.05),以及透析期间的平均透析液钙浓度、血液碳酸氢盐浓度和透析开始时的残余肾功能(分别为p<0.01、p<0.05和p<0.005)。相比之下,持续性非卧床腹膜透析患者的碳酸钙总剂量低于血液透析患者(p<0.01)。骨矿物质密度结果以Z评分表示(根据年龄和性别调整的623名健康受试者骨矿物质密度适当平均值的标准差数量)。在腰椎,三组之间未观察到骨矿物质密度的显著差异。在股骨颈和胫骨骨骺,血液透析患者的骨矿物质密度低于正常对照组(p<0.001),而血液透析患者和持续性非卧床腹膜透析患者之间未观察到差异。在胫骨干骺端,血液透析患者的骨矿物质密度低于持续性非卧床腹膜透析患者和正常对照组(p<0.001),持续性非卧床腹膜透析患者和正常对照组的值相似。在血液透析(n = 25)和持续性非卧床腹膜透析(n = 25)患者的透析持续时间精确匹配后(分别为1.9±0.3年和1.7±0.3年),结果保持一致。多元回归分析显示,一方面腰椎(p<0.05)、股骨颈(p<0.02)、胫骨干骺端(p<0.005)和胫骨骨骺(p<0.05)的Z评分与另一方面血浆碱性磷酸酶活性之间存在显著负相关。胫骨干骺端Z评分也与透析开始时的残余肾功能相关(p<0.05)。总之,本研究为持续性非卧床腹膜透析相对于血液透析对皮质骨的保护提供了证据。在前一种治疗方式中观察到的较高残余肾功能可能至少部分解释了这一发现。